Fed. Circ. Won't Revive Novartis Hemophilia Drug IP Suit
By Ben James ( August 23, 2011, 5:32 PM EDT) -- The Federal Circuit on Tuesday rejected a bid from Genetics Institute LLC to revive a suit against Novartis Vaccines & Diagnostics Inc. claiming that a GI patent for the formula for hemophilia treatment ReFacto had priority of invention over two Novartis patents....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.